Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Georgi Mihaylov"'
Autor:
Alexander Egle, Thomas Melchardt, Petra Obrtlíková, Lukáš Smolej, Tomáš Kozák, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikušková, Liana Gercheva, Thomas Nösslinger, Tomáš Papajík, Miriam Ladická, Michael Girschikofsky, Mikuláš Hrubiško, Ulrich Jäger, Daniela Voskova, Martin Pecherstorfer, Eva Králiková, Christina Burcoveanu, Emil Spasov, Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emília Flochová, Stanislav Palášthy, Olga Stehlíková, Michael Doubek, Petra Altenhofer, Lukas Weiss, Teresa Magnes, Lisa Pleyer, Anton Klingler, Jiří Mayer, Richard Greil
Publikováno v:
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
Abstract No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing i
Externí odkaz:
https://doaj.org/article/5fbc792402b144bb941d23c116493c05
Autor:
Stein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, Vinko Tosevski, Krzysztof Warzocha, Claudia Dumrese, Augustin Ferrant, Tobias Gedde-Dahl, Andrzej Hellmann, Jeroen Janssen, Boris Labar, Alois Lang, Waleed Majeed, Georgi Mihaylov, Jesper Stentoft, Leif Stenke, Josef Thaler, Noortje Thielen, Gregor Verhoef, Jaroslava Voglova, Gert Ossenkoppele, Andreas Hochhaus, Henrik Hjorth-Hansen, Satu Mustjoki, Sieghart Sopper, Francis Giles, Kimmo Porkka, Dominik Wolf, Bjørn Tore Gjertsen
Publikováno v:
Haematologica, Vol 102, Iss 8 (2017)
Monitoring of single cell signal transduction in leukemic cellular subsets has been proposed to provide deeper understanding of disease biology and prognosis, but has so far not been tested in a clinical trial of targeted therapy. We developed a comp
Externí odkaz:
https://doaj.org/article/e5220aa38eb9478f96396fc7b61232c4
Autor:
Jane Hippenmeyer, Nikolai Tzvetkov, Katja Björklöf, Zuzana Sninska, Vladlen Ivanushkin, Georgi Mihaylov, Barbara Skopec
Publikováno v:
Hematology. 26:497-502
OBJECTIVES The objective of this analysis was to assess the effectiveness and safety of romiplostim in the real-world by duration of primary immune thrombocytopenia (ITP): 12 ('chronic') months. METHODS This was a post-hoc analysis of the PLATON sing
Autor:
Ella Willenbacher, Zita Borbényi, Steffen Koschmieder, Robert Kralovics, Mario Cazzola, Uwe Platzbecker, Emanuil Gheorghita, Pencho Georgiev, Heinz Gisslinger, Mathieu Puyade, Malgorzata Calbecka, Jerome Rey, Kurt Krejcy, Jiri Mayer, Krzysztof Warzocha, Emilie Cayssials-Caylus, Veronika Buxhofer-Ausch, János Jakucs, Anna Vallova, Georgi Mihaylov, Hans Carl Hasselbalch, Lydia Roy, Vera Yablokova, Olga Cerna, Aleksander Skotnicki, Richard Greil, Jiri Schwarz, Vera Stoeva, Lylia Sivcheva, Zvenyslava Masliak, Halyna Pylypenko, Antonia Hatalova, Delia Dima, Jose Miguel Torregrosa-Diaz, Elena Volodicheva, Jean-Jacques Kiladjian, S V Klymenko, Carlos Besses Raebel, Polina Kaplan, Irina Sokolova, Horia Bumbea, Miklos Egyed, Nicoleta Berbec, Barbara Grohmann-Izay, Alexander Myasnikov, Petr Dulicek, Tamila Lysa, Dominik Wolf, Andrei Cucuianu, Christoph Klade, Mihaela Lazaroiu, Maria Soroka-Wojtaszko, Tamás Masszi, Ernst Forjan, Liana Gercheva-Kyuchukova, Franz Bauer, Dorota Krochmalczyk, Árpád Illés, Mikulas Hrubisko, Jolanta Starzak-Gwozdz, Viktor Rossiev
Publikováno v:
The Lancet Haematology. 7:e196-e208
Summary Background The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. Methods PRO
Autor:
Peter Černelč, Vladlen Ivanushkin, Nikolai Tzvetkov, Barbara Skopec, Katja Björklöf, Georgi Mihaylov, Daniela Niepel, Zuzana Sninska, O. Černá
Publikováno v:
memo - Magazine of European Medical Oncology. 13:227-234
SummaryChronic primary immune thrombocytopenia (ITP) is an autoimmune disease involving the formation of antibodies to thrombocytes, leading to increased platelet destruction and chronic thrombocytopenia. Additionally, impaired platelet production is
Autor:
Keranka Dimitrova, Sashka Krumova, Lidia Gartcheva, Georgi Mihaylov, Svetla Todinova, Stefka G. Taneva, Avgustina Danailova, Violeta Petkova, Margarita Guenova
Publikováno v:
Thermochimica Acta. 655:351-357
The thermodynamic stability of biofluids is currently extensively studied by means of differential scanning calorimetry (DSC), a biophysical technique that measures thermally induced conformational transitions of biomolecules in solution. In this wor
Autor:
Georgi Mihaylov
Publikováno v:
International conference KNOWLEDGE-BASED ORGANIZATION. 23:187-191
The article examines cases of conflict between the national law of the EU Member States and European Union Law. There is an analysis of the legal advantage of EU law over national law or vice versa. Conclusions have been drawn that the national law s
Autor:
Ivan Spicka, Andrzej Jakubowiak, Tamas Masszi, Maria-Victoria Mateos, Jiri Minarik, Hervé Avet-Loiseau, Mihaela Obreja, Albert Oriol, William I. Bensinger, Rafael Fonseca, Georgi Mihaylov, Vesselina Goranova-Marinova, A. Keith Stewart, Vishal Kukreti, Michael Wang, Laura Rosiñol, Meletios A. Dimopoulos, Vladimir Maisnar, David A. Siegel, Ruben Niesvizky, Antonio Palumbo, Roman Hájek, Philippe Moreau, Dina Ben-Yehuda
Publikováno v:
Blood. 128:1174-1180
The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact on survival in multiple myeloma (MM). The phase 3 study ASPIRE (N = 792) demonstrated that
Autor:
Roumyana Petrova, Andrea Cipkova, Jan Novak, Zhasmina Mihaylova, Lubos Drgona, Georgi Mihaylov
Publikováno v:
memo - Magazine of European Medical Oncology. 9:144-152
Febrile neutropenia (FN) is a common side effect of chemotherapy that frequently necessitates hospitalization and healthcare resource utilization (HCRU), but is poorly studied in Eastern European countries. We investigated HCRU and granulocyte colony
Autor:
Emília Flochová, Eva Mikuskova, Tomas Papajik, Michael Girschikofsky, Jiří Mayer, Liana Gercheva, Petra Altenhofer, Michael Steurer, Ulrich Jäger, Mikulas Hrubisko, August Zabernigg, Georgi Mihaylov, Lukas Smolej, Miriam Ladická, Lisa Pleyer, Sonja Burgstaller, Horst Oexle, Emil Spasov, Michael A. Fridrik, Richard Greil, Julian Raynov, Thomas Nösslinger, Eva Králiková, Olga Stehlíková, Alexander Egle, Cristina Burcoveanu, Martin Pecherstorfer, Thomas Melchardt, Anton Klingler, Stanislav Palasthy, Petra Obrtlikova, Michael Doubek, Tomas Kozak, Andreas L. Petzer, Johannes Andel
Publikováno v:
The Lancet Haematology. 3:e317-e329
Summary Background In many patients with chronic lymphocytic leukaemia requiring treatment, induction therapy with rituximab plus chemotherapy improves outcomes compared with chemotherapy alone. In this study we aimed to investigate the potential of